On May 28, Zai Lab fell 5.03% in regular trading, trading at 13.62 HKD/share, with trading volume of 122 million HKD. The decline reflects compounding negative catalysts from a senior executive departure and deteriorating fundamentals.

On May 22, the company announced that the board decided Josh Smiley would no longer serve as President and COO, effective May 18. This marks the second major executive departure following the Chief Commercial Officer's exit in 2024. Smiley's removal was characterized as a non-voluntary departure. Founder and CEO Samantha Du will assume his responsibilities.

The leadership shakeup coincides with weak Q1 results: total revenue of $99.6 million fell 6% year-over-year, with core product Zejula (niraparib) revenue declining nearly 40%. Net loss reached $51 million. The market has directly linked the executive dismissal to Q1 underperformance, amplifying near-term operational uncertainty.

The broader biotech sector was also under pressure, with INNOVENT BIO down 5.07%, AKESO down 4.69%, and 3SBIO down 7.66%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)